By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galectin Therapeutics 

7 Wells Avenue, Suite #34

Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


Company News
Galectin Therapeutics Begins Phase IIa Psoriasis Study With GR-MD-02 9/24/2015 8:04:45 AM
Galectin Therapeutics To Present At 2015 Ladenburg Thalmann Healthcare Conference 9/22/2015 8:26:56 AM
Galectin Therapeutics Announces Start Of Phase 2 Clinical Trial With GR-MD-02 In NASH With Advanced Fibrosis 9/16/2015 6:19:28 AM
Galectin Therapeutics To Participate In Three Investment Conferences In September 9/8/2015 2:48:00 PM
Galectin Therapeutics Receives U.S. Patent Notice Of Allowance For Use Of Pectin Compounds To Reduce Fibrosis In Multiple Diseases 8/13/2015 7:45:31 AM
Galectin Therapeutics Provides Phase II NASH Program Update and Reports Second Quarter 2015 Financial Results 8/10/2015 7:40:34 AM
Exalenz Bioscience Announces Collaboration With Galectin Therapeutics To Use BreathID To Monitor Patients With Cirrhosis Associated With NASH 8/3/2015 6:24:23 AM
Galectin Therapeutics Appoints Adam E. Allgood, Pharm.D., R.Ph., As Executive Director Of Clinical Development 7/16/2015 7:39:04 AM
Galectin Therapeutics Initiates Enrollment For GR-MD-02 Phase II Clinical Trial In NASH With Cirrhosis 6/29/2015 7:27:47 AM
Galectin Therapeutics Names Dr. Marc Rubin Lead Independent Director 6/3/2015 7:35:37 AM